Environmental

XOMA’s low R&D intensity versus peers suggests a lighter direct environmental footprint from laboratory and development activity, but this also limits evidence of superior resource efficiency.

The company’s capital-light profile likely reduces emissions and waste exposure relative to larger biotech peers with heavier manufacturing footprints, though disclosed environmental metrics remain limited.

No material environmental controversies were provided, which supports a neutral-to-slightly-better peer position, but the absence of detailed disclosure constrains confidence in the assessment.

Compared with peers that operate more asset-intensive facilities, XOMA appears less exposed to energy, water, and hazardous-waste intensity, yet this advantage is not strongly evidenced in filings.

Social

XOMA’s stock-based compensation at 10.8% of revenue indicates meaningful employee alignment, but it also suggests peer-level pressure on retention and dilution-related stakeholder concerns.

A relatively small operating footprint can reduce workforce and community exposure versus larger biotech peers, but it also limits the scale of disclosed social programs and impact.

No labor, product-safety, or access-to-medicine controversies were provided, which supports a steadier social profile than peers with more visible operational or clinical risks.

Compared with diversified healthcare companies, XOMA likely faces fewer broad social obligations, but its limited disclosure makes it harder to demonstrate leadership on human-capital practices.

Governance

XOMA’s debt-to-equity ratio of 1.10 and net debt-to-EBITDA of 0.60 indicate manageable leverage, but peer-relative governance strength depends more on capital discipline and oversight quality.

High gross margin and low R&D intensity suggest disciplined capital allocation, yet the absence of detailed governance disclosures limits evidence of superior board or control practices.

Stock-based compensation at 10.8% of revenue can align management with shareholders, but it may also raise peer-relative concerns about dilution and incentive calibration.

No major governance controversies were provided, which supports a stable baseline versus peers, although the available metrics do not indicate a clear governance advantage.

Overall Score

XOMA’s ESG profile is broadly in line with peers, with modest advantages from a lighter operating footprint offset by limited disclosure and only average governance evidence.

Score Driver: Limited ESG Disclosure Prevents A Stronger Peer-Relative Assessment Despite A Comparatively Light Operational Footprint.